Ibandronsäure +pharma (Ibandronic Acid Monosodium Salt, Monohydrate)

Ibandronic acid binds to hydroxyapatite on bone surfaces and is taken up by osteoclasts during bone remodeling. Inside the cell it blocks the enzyme farnesyl pyrophosphate synthase, disrupting the mevalonate pathway, which impairs osteoclast activity and induces apoptosis, leading to reduced bone resorption.

The dosing regimen for Ibandronsäure +pharma is determined by the prescribing physician based on the patient’s clinical condition, renal function, and other individual factors. Healthcare professionals set the appropriate dose and infusion schedule according to approved guidelines.

Safety data for ibandronic acid in pregnancy and lactation are limited, and the product is generally not recommended for use in pregnant or nursing women. Clinicians should weigh potential risks against benefits and consider alternative therapies when treating women of childbearing potential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ibandronsäure +pharma is administered intravenously, offering a rapid infusion option compared with oral bisphosphonates that require strict dosing schedules and fasting. Its potency in inhibiting osteoclast activity is comparable to other IV agents such as zoledronic acid, but the safety profile and dosing frequency may differ, influencing clinical choice.

The product must be stored at 2‑8 °C in a refrigerator, protected from light, and should not be frozen or shaken. Before use, allow the vial to reach room temperature if required, and handle it with aseptic technique to maintain sterility.

Ibandronsäure +pharma is given as an intravenous infusion over a short period, typically 15 minutes, under medical supervision. The infusion is performed in a clinical setting where vital signs can be monitored, and patients are observed for any acute reactions during and after the administration.

Serious risks include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment, acute hypersensitivity reactions, and cardiac arrhythmias such as atrial fibrillation. Patients should be monitored closely for signs of these conditions, and treatment should be discontinued if they occur.

Ibandronsäure +pharma is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to ibandronic acid or any formulation components, and those with active dental infections or recent jaw surgery. Caution is also advised for pregnant or breastfeeding women.